Literature DB >> 169861

Methanol extraction residue of BCG in the treatment of transplanted rat tumours.

D G Hopper, M V Pimm, R W Baldwin.   

Abstract

Subcutaneous growth of immunogenic chemically induced rat sarcomata and a hepatoma was restricted when cells were injected into syngeneic animals in admixture with MER. Rats rejecting mixed inocula were immune to further challenge with the same tumour. Growth of a chemically induced mammary carcinoma which lacks detectable immunogenicity was suppressed when low cell inocula were injected in admixture with MER or intact BCG organisms, although animals were not immune to re-challenge. These studies indicate that clinically MER may be a suitable alternative to BCG for contact suppression of tumour growth or incorporation into tumour cell:adjuvant vaccines for active immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 169861      PMCID: PMC2009408          DOI: 10.1038/bjc.1975.23

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Immunotherapy of melanoma with intralesional BCG.

Authors:  R S Bornstein; M J Mastrangelo; H Sulit; D Chee; J W Yarbro; L M Prehn; R T Prehn
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

2.  Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guérin strain of Mycobacterium bovis.

Authors:  G L Bartlett; B Zbar; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1972-01       Impact factor: 13.506

3.  Tumor regression mediated by Mycobacterium bovis (strain BCG). Effects of isonicotinic acid hydrazide, cortisone acetate, and antithymocyte serum.

Authors:  E B Chung; B Zbar; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1973-07       Impact factor: 13.506

4.  Radiation-killed BCG in the treatment of transplanted rat tumours.

Authors:  R W Baldwin; A J Cook; D G Hopper; M V Pimm
Journal:  Int J Cancer       Date:  1974-06-15       Impact factor: 7.396

5.  Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: safety and efficacy.

Authors:  G L Bartlett; B Zbar
Journal:  J Natl Cancer Inst       Date:  1972-06       Impact factor: 13.506

6.  Tumor suppression by cell walls of mycobacterium bovis attached to oil droplets.

Authors:  B Zbar; H J Rapp; E E Ribi
Journal:  J Natl Cancer Inst       Date:  1972-03       Impact factor: 13.506

7.  Granulomatous hepatitis: a complication of B.C.G. immunotherapy.

Authors:  J S Hunt; M J Silverstein; F C Sparks; C M Haskell; Y H Pilch; D L Morton
Journal:  Lancet       Date:  1973-10-13       Impact factor: 79.321

8.  Immunotherapy in well-controlled chronic myelocytic leukemia.

Authors:  J E Sokal; C W Aungst; J T Grace
Journal:  N Y State J Med       Date:  1973-05-15

9.  Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy.

Authors:  D L Morton; F R Eilber; W L Joseph; W C Wood; E Trahan; A S Ketcham
Journal:  Ann Surg       Date:  1970-10       Impact factor: 12.969

10.  B.C.G. suppression of pulmonary metastases from primary rat hepatomata.

Authors:  R W Baldwin; M V Pimm
Journal:  Br J Cancer       Date:  1974-11       Impact factor: 7.640

View more
  4 in total

1.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

2.  Treatment of transplanted rat tumours with double-stranded RNA (BRL 5907). I. Influenced of systemic and local administration.

Authors:  M V Pimm; M J Embleton; R W Baldwin
Journal:  Br J Cancer       Date:  1976-02       Impact factor: 7.640

3.  Stimulation of anti-tumour immunity in guinea-pigs by methanol extraction residue of BCG.

Authors:  M A Wainberg; V Deutsch; D W Weiss
Journal:  Br J Cancer       Date:  1976-11       Impact factor: 7.640

4.  BCG treatment of malignant pleural effusions in the rat.

Authors:  M V Pimm; D G Hopper; R W Baldwin
Journal:  Br J Cancer       Date:  1976-10       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.